ResMed Inc. (RMD) Research Coverage Started at JPMorgan Chase & Co.
Analysts at JPMorgan Chase & Co. initiated coverage on shares of ResMed Inc. (NYSE:RMD) in a report released on Tuesday. The firm set a “neutral” rating and a $64.00 price target on the stock.
Several other research firms also recently issued reports on RMD. Needham & Company LLC reissued a “sell” rating on shares of ResMed in a research report on Monday, September 12th. Jefferies Group lifted their price target on shares of ResMed from $56.00 to $60.00 and gave the company a “hold” rating in a research report on Friday, July 29th. Northland Securities set a $50.00 price target on shares of ResMed and gave the company a “sell” rating in a research report on Monday, August 29th. Bank of America Corp. reissued a “hold” rating and issued a $65.00 price target on shares of ResMed in a research report on Sunday, July 10th. Finally, Zacks Investment Research downgraded shares of ResMed from a “hold” rating to a “sell” rating in a research report on Friday, July 8th. Five analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. ResMed presently has a consensus rating of “Hold” and an average target price of C$60.10.
ResMed (NYSE:RMD) traded down 0.88% during trading on Tuesday, hitting $63.93. 1,240,322 shares of the company’s stock traded hands. The company has a market cap of $8.99 billion, a PE ratio of 25.67 and a beta of 0.68. ResMed has a 52-week low of $50.77 and a 52-week high of $70.90. The company’s 50 day moving average price is $65.76 and its 200 day moving average price is $62.49.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/09/resmed-inc-rmd-research-coverage-started-at-jpmorgan-chase-co.html
ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.74 EPS for the quarter, hitting the consensus estimate of $0.74. The company earned $518.60 million during the quarter, compared to the consensus estimate of $512.37 million. ResMed had a net margin of 18.63% and a return on equity of 23.89%. The company’s quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.68 EPS. Analysts expect that ResMed will post $2.88 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 22nd. Investors of record on Thursday, August 18th were issued a dividend of $0.33 per share. This represents a $1.32 dividend on an annualized basis and a yield of 2.06%. The ex-dividend date was Tuesday, August 16th. This is an increase from ResMed’s previous quarterly dividend of $0.30. ResMed’s dividend payout ratio (DPR) is 54.32%.
In other ResMed news, Director Richard Sulpizio sold 36,000 shares of the stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of C$70.15, for a total transaction of C$2,525,400.00. Following the completion of the transaction, the director now owns 101,887 shares in the company, valued at C$7,147,373.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Peter C. Farrell sold 20,000 shares of the stock in a transaction dated Tuesday, October 4th. The stock was sold at an average price of C$64.70, for a total transaction of C$1,294,000.00. Following the transaction, the director now owns 364,063 shares of the company’s stock, valued at approximately C$23,554,876.10. The disclosure for this sale can be found here. Corporate insiders own 1.97% of the company’s stock.
A number of institutional investors have recently modified their holdings of the company. Aperio Group LLC raised its position in shares of ResMed by 27.7% in the first quarter. Aperio Group LLC now owns 35,053 shares of the company’s stock worth $2,027,000 after buying an additional 7,597 shares in the last quarter. Virginia Retirement System acquired a new position in shares of ResMed during the first quarter worth $622,000. CIBC World Markets Inc. acquired a new position in shares of ResMed during the first quarter worth $264,000. Ngam Advisors L.P. acquired a new position in shares of ResMed during the first quarter worth $1,080,000. Finally, TIAA CREF Investment Management LLC raised its position in shares of ResMed by 34.0% in the first quarter. TIAA CREF Investment Management LLC now owns 650,942 shares of the company’s stock worth $37,637,000 after buying an additional 165,025 shares in the last quarter. Hedge funds and other institutional investors own 61.07% of the company’s stock.
ResMed Inc is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories.
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.